^
CANCER:

Endometrial Adenocarcinoma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
HER-2 expression
Endometrial Adenocarcinoma
trastuzumab
Sensitive
:
A2
No biomarker
Endometrial Adenocarcinoma
ZN-c3
Sensitive
:
B
HER-2 overexpression
Endometrial Adenocarcinoma
trastuzumab
Sensitive
:
C1
HER-2 positive
Endometrial Adenocarcinoma
trastuzumab
Sensitive
:
C1
MSI-H/dMMR
Endometrial Adenocarcinoma
AZD1775
Sensitive
:
C3
HER-2 positive
Endometrial Adenocarcinoma
trastuzumab
Sensitive
:
C3
ER positive
Endometrial Adenocarcinoma
letrozole
Sensitive
:
C4
MSH6 F1088fs
Endometrial Adenocarcinoma
pembrolizumab
Sensitive
:
C4
HER-2 amplification
Endometrial Adenocarcinoma
lapatinib
Sensitive
:
D
HER-2 amplification
Endometrial Adenocarcinoma
trastuzumab + lapatinib
Sensitive
:
D
HER-2 amplification
Endometrial Adenocarcinoma
afatinib
Sensitive
:
D